Actually, there is a way to use it if you take the proper precautions. The Bonferroni correction provides statistical protection against a random false positive.
I should also point out that if CHMP accepts the validity of the ABCLEAR3 group, the ADL issue disappears. ABCLEAR3 patients showed stat sig on ADL.
For re-examination new data cannot be added, new analysis on existing data provided with the MAA can. If we assume that all the available trial participant gene data was included, then the question becomes if the GWAS database extract is considered data that should have been part if the MAA or if it passes as necessary external input to the analysis.
Maybe someone can do the exercise with ChatGPT to see if an answer with references can be pinned down.
Market Data 
Markets 
AI
